

REVOLUTIONIZING PHARMA: HOW AI IS SHAPING PHARMACEUTICAL SECTOR

ABSTRACT:

The pharmaceutical sector has been playing a crucial role in the innovation, development, discovery and delivery of novel drugs. This article explains about the role of Artificial intelligence (AI), which has nowadays become an integral part of the pharmaceutical sector in drug discovery. It also includes different AI models like Deep Chem, RDKit, ChemBERTa, Auto Dock Vina and some other that has been used at different stages of drug discovery. The article gives us an insight about the contributions of AI in drug delivery, drug design, in biological product development and in medical devices.

KEYWORDS: Pharmaceutical sector, artificial intelligence (AI), innovation, drug discovery, biological product development.

INTRODUCTION:

Artificial Intelligence is a computer science field that involves accumulating knowledge, creating rules, and replicating human behaviour. AI aims at developing autonomous computer systems that require minimum or no human involvement. In 1956, a workshop on the Dartmouth College campus established the subject of artificial intelligence research. The workshop speakers went on to become decades-long innovators in AI research. Many of them believed that machines as intelligent as humans would exist within one generation. AI helps these models learn, understand, and analyse data. Artificial intelligence (AI) is rapidly impacting industries, including the pharmaceutical industry. Many companies, with a significant change occurring in the pharmaceutical sector. AI is being used more and more in

the pharmaceutical sector, especially in pharmaceutical research, to automate, improve, and personalize a variety of processes. Traditional drug development techniques are typically expensive, tedious, and inefficient; they frequently take several decades and cost billions of dollars. AI improves medication design by more accurately predicting behaviour, interactions, and qualities. These approaches promote precision in drug discovery and lower clinical trial expenses, resulting in more effective medications ^[1].

How AI started: American computer scientist and inventor John McCarthy was known as the "Father of Artificial Intelligence" after he introduced the field dedicated to the research and creation of intelligent machines.

Alan Turing's "Computer Machinery and Intelligence" was released in 1950, and it presented The Imitation Game, a machine intelligence test. In 1952, Arthur Samuel, a computer scientist, created the first checkers program that could learn the game on its own.

Various aspects of drug manufacturing can also benefit from AI

- AI has the potential to revive nanomedicine and dose optimization. A patient's unique disease profile is assembled using diagnostic nanomaterials, and an array of therapeutic nanotechnologies is then applied to improve the treatment's outcome.
- AI may promote quick novel drug discoveries and build protocols for the production of these new molecules, as well as predicting the preferred chemical structure and gaining knowledge of potential drug-target interactions.^[2]
- Marketing - strategies are required in many businesses, including the pharmaceutical industry. Many e-commerce sites currently use AI for effective marketing, and the pharmaceutical industry can greatly profit from the same method.

ROLE OF AI IN PHARMACEUTICAL SCIENCES

AI's position in pharmaceutical sciences encompasses a wide range of research fields that contribute to the discovery, development, and formulation of drug products.

In the development of drug delivery systems

Machine learning has potential applications in various sectors, including healthcare, pharmacology, and biological sciences. Machine learning is utilized in the pharmaceutical sector for several operations, including grinding, mixing, granulating, drying, filling, packing, and testing. Machine learning is used for genetic data sequencing, coding, and recognition to produce biomedicines ^[2]. Computer vision, a branch of AI that uses deep learning and pattern recognition, can understand graphs, tables, photos, and other text and video in PDF documents. This technology is used to analyse X-rays and speed up patient diagnostics. Computer vision is used to recognize chemical components, build complexes, and study genetic structures ^[3]. AI techniques can improve pharmaceutical delivery by stimulating, predicting, and optimizing drug distribution in patients. Artificial neural networks, machine learning, and deep learning are being utilized to automate and optimize pharmaceutical manufacturing and delivery. Machine learning (ML) and DL systems can improve therapeutic results and help in medication selection and dosing ^[4]. Nanomedicine relies on these properties since nanocarriers can contain numerous therapies and be administered to patients with different medical conditions. The pharmaceutical sector can greatly benefit from combining AI, particularly in drug research and administration.

PAT (Process Analytical Technology)

Process Analytical Technology (PAT) is defined by the Food and Drug Administration (FDA) as a method for designing, analysing, and controlling pharmaceutical manufacturing processes by recognizing important process parameters that impact important quality attributes of an

Active Pharmaceutical Ingredient (API) during manufacturing. Machine learning techniques and artificial intelligence approaches have become crucial for better managing the drug development process. These models use data from the real world to guide their predictions and design choices, improving process output, uniformity and quality. In conclusion, we can state that the pharmaceutical sector is changing as a result of the use of quality-by-design principles along with machine learning and modern technology. By promoting risk management, understanding of products and processes, and continuous improvement, QbD is opening the door to more affordable, safer, and more efficient drug formulations ^[5].

Healthcare

AI has an important part in drug discovery, including developing new compounds and identifying new biological targets. It is essential for identifying and validating pharmacological targets using many approaches, including target-based, phenotypic, and multi-target drug discoveries, as well as repurposing and biomarker discovery. AI can help pharmaceutical companies speed up drug approval and market launch, particularly when integrated into research. Growth can result in cost savings, making pharmaceuticals easier to get to patients and increasing treatment options. Artificial intelligence (AI) has the potential to improve efficiency and accessibility in the pharmaceutical industry ^[6].

Role of AI in drug discovery

A significant change in pharmaceutical research has been generated by the application of artificial intelligence (AI) in drug discovery, which integrates advanced computer methods with traditional scientific investigation to overcome a long-standing difficulty ^[7]. It examines how AI is used to predict drug attributes like toxicity, bioactivity, and physicochemical aspects as well as in drug design, polypharmacology, chemical synthesis, and drug repurposing. The study discusses the difficulties and restrictions faced in the sector, such as data quality,

generalizability, computing demands, and ethical implications, despite AI's favourable developments^[8].

Role of AI in drug delivery

Computational pharmaceutics use AI and big data to improve the distribution of drugs through multiscale simulation. Computational pharmaceutics analyses immense data sets using AI algorithms and machine learning techniques to predict drug actions. Creating healthcare formulation and distribution processes helps researchers to evaluate and optimize systems without expensive trial-and-error studies. This leads to faster medication development, lower costs, and increase productivity^[9]. Computational pharmaceutics models drug delivery systems at various levels, including molecular interactions and macroscopic behaviour. AI algorithms may evaluate medication characteristics, formulation components, and physiological aspects that predict behaviour at various levels from the time the medication enters the body till it is excreted. From the beginning, in the development stage, researchers are able to identify all risks or challenges related to drug delivery methods by using the correct set of AI technologies^[10]. Therefore, it is possible to make early modifications and adjustments that minimize risks and enhance the effectiveness of medicines. Unexpected results become less possible when AI and computational modelling are used instead of expensive and time-consuming trial-and-error examinations.

AI in drug design

In the field of drug design, AI greatly speeds up the drug development by improving the identification process of potential lead compounds^[11]. The ability of AI to evaluate a broad range of molecular configurations and forecast their possible binding affinities, streamlining the pathway from concept to clinic^[12]. The study of protein structures is an important aspect of drug discovery, as many diseases are associated with protein dysfunction. AI is used to

predict 3D protein structures with greater accuracy, allowing for the study of protein-protein interactions (PPI) and further understanding of structural drug design^[13,14].

Predicting the 3D structure of target protein

One of the most crucial processes in structure-based drug design and discovery is predicting the three-dimensional (3D) structure of target proteins. In order to predict the three-dimensional structure of proteins from their sequences, artificial intelligence (AI) models carefully extract characteristics associated with amino acid properties, structural motifs, and evolutionary history^[15]. AlphaFold, developed by Google DeepMind, is a significant advancement in AI-driven protein structure prediction. AlphaFold predicts the 3D target protein structure by evaluating the angles of peptide bonds and the distances between nearby amino acids^[16,17].

Prediction of Drug – Protein interactions

A key aspect of efficient drug development is the prediction of drug-protein interactions (DPIs), which greatly benefits from the application of AI. AI enables the study of huge biological and chemical datasets^[18,19]. AI tools excel at discovering important variables that affect DPIs by evaluating molecular data, allowing them to assess potential interactions between novel drug possibilities based on their chemical compositions. Accurate detection of ligand-protein interactions is essential for understanding therapeutic efficacy, enabling drug repurposing, and lowering the risk associated with polypharmacology^[20]. AI approaches have been essential in making exact predictions of these interactions, resulting in improved therapeutic outcomes.

AI in Medical Devices

A medical device is a type of apparatus, tool, instrument, implant, or machine appliance that serves a specific medical purpose and can be used alone or in conjunction with software or other related systems in vitro and intended for medical use^[21].

Some examples of utilization of AI in medical devices include:

1. Diagnostic Assistance
2. Remote Monitoring of vitals
3. Wearable Devices
4. Prosthetics and Rehabilitation
5. Medication Management

AI TOOLS FOR BIOLOGICAL PRODUCT DEVELOPMENT

AI facilitates the development of novel proteins, peptides, nucleic acid biologics, and Immunotherapeutics with desired characteristics ^[22]. AI algorithms can identify therapeutic targets based on genomic, proteomic, and clinical data. It assists researchers in developing protein and peptide biologics that modify biological pathways or target illness-causing proteins by identifying disease targets ^[23]. AI algorithms predict:

1. Protein/peptide-target molecule binding affinity
2. Protein and peptide biologic toxicity
3. Predict harmful sequence and structure
4. Protein folding from amino acid sequences

APPLICATION OF AI IN SCIENTIFIC FIELDS

In Genomics: Mainly used in genetic variant identification, gene function prediction and analysis of genomic interactions. AI is mainly advantageous in rapid processing of sequencing data and has improved accuracy in predicting regulatory elements.

In climate science: Used in climate model improvement, satellite imagery analysis, extreme weather prediction. The ability to accurately predict both short-term weather patterns and long-term climate trends is using AI models.

Different AI tools used for drug discovery ^[24]

TABLE 1: Role of AI in drug discovery

AI tools	Role in drug discovery
DeepChem	An open-source library that offers a wide range of tools and models for drug development, including deep learning models for molecular property prediction, virtual screening, and generative chemistry.
RDKit	A prominent open-source cheminformatics library offers features for molecule handling, substructure searching, and descriptor calculation.
ChemBERTa	A linguistic approach developed primarily for drug discovery tasks. It relies on the Transformer architecture and pre-trained on a significant body of chemical and biomedical literature, allowing it to synthesize molecular structures, forecast characteristics, and aids in lead optimization.
IBM RXN for Chemistry	An artificial intelligence model meant to anticipate chemical reactions. It uses deep learning algorithms and massive reaction datasets to produce potential reaction outcomes, hence assisting in the development of new synthetic routes and compounds.
scape-DB	scape-DB (Extraction of Chemical and Physical Properties from the Literature-DrugBank) is a database that uses natural language processing and machine learning to extract chemical and biological information from scientific publications. It offers useful information for drug discovery research.

Conclusion: Artificial intelligence is shaping the future of pharmaceutical industry's, bringing innovations and advancement that promise to improve efficacy of treatment, reducing costs, and accelerating the development of new drugs. The goal of AI is to enhance human lives and address complex challenges arising in various fields, ranging from healthcare to environmental sustainability.

Disclaimer (Artificial intelligence)

Author(s) hereby declare that NO generative AI technologies such as Large Language Models (ChatGPT, COPILOT, etc.) and text-to-image generators have been used during the writing or editing of this manuscript.

References:

1. Singh, S., Kaur, N., & Gehlot, A. (2024). Application of artificial intelligence in drug design: A review. *Computers in Biology and Medicine*, 179, 108810. <https://doi.org/10.1016/j.combiomed.2024.108810>
2. Mason DJ. Using machine learning to predict synergistic antimalarial compound combinations with novel structures. *Front. Pharmacol.* 2018;9:1096.
3. Shahiwala A. AI approaches for the development of drug delivery systems. A Handbook of Artificial Intelligence in Drug Delivery, Academic Press, 2023, Pages 83-96. <https://doi.org/10.1016/B978-0-323-89925-3.00004-6>.
4. Taher M, Susanti D, Hamzah N, Aminudin NI, Ismail MW, Danial WH, Shafiee SA, Md Ali MA , Zahir Ramli MZ. Relevance of AI in microbased drug delivery system. A Handbook of Artificial Intelligence in Drug Delivery, Academic Press, 2023, Pages 123-143. <https://doi.org/10.1016/B978-0-323-89925-3.00006-X>.
5. Prusty, A., & Panda, S. K. (2024). The Revolutionary Role of Artificial Intelligence (AI) in Pharmaceutical Sciences. *Indian Journal of Pharmaceutical Education and Research*, 58(3s), s768–s776. <https://doi.org/10.5530/ijper.58.3s.78>.

6. Rakočević, T., & Markovic, M. (2024). Assessing the impact of AI: the case of the pharmaceutical industry. *European Journal of Business Management and Research*, 9(5), 70–75. <https://doi.org/10.24018/ejbmr.2024.9.5.2461>.
7. Abbas, M. K. G., Rassam, A., Karamshahi, F., Abunora, R., & Abouseada, M. (2024). The Role of AI in Drug Discovery. *ChemBioChem*, 25(14). <https://doi.org/10.1002/cbic.202300816>.
8. Chavda V.P., Vihol D., Patel A., Redwan E.M., Uversky V.N. *Bioinformatics Tools for Pharmaceutical Drug Product Development*. John Wiley & Sons, Ltd.; Hoboken, NJ, USA: 2023. Introduction to Bioinformatics, AI, and ML for Pharmaceuticals; pp. 1–18.
9. Lou H., Lian B., Hageman M.J. Applications of Machine Learning in Solid Oral Dosage Form Development. *J. Pharm. Sci.* 2021;110:3150–3165. doi: 10.1016/j.xphs.2021.04.013.
10. Jiang J., Ma X., Ouyang D., Williams R.O. Emerging Artificial Intelligence (AI) Technologies Used in the Development of Solid Dosage Forms. *Pharmaceutics*. 2022;14:2257. doi: 10.3390/pharmaceutics14112257.
11. Hasselgren, C., & Oprea, T. I. (2023). Artificial Intelligence for Drug Discovery: Are We There Yet? *The Annual Review of Pharmacology and Toxicology*, 64(1), 527–550. <https://doi.org/10.1146/annurev-pharmtox-040323-040828>.
12. Deng, J., Yang, Z., Ojima, I., Samaras, D., & Wang, F. (2021). Artificial intelligence in drug discovery: applications and techniques. *Briefings in Bioinformatics*, 23(1). <https://doi.org/10.1093/bib/bbab430>.
13. Dara, S., Dhamercherla, S., Jadav, S. S., Babu, C. M., & Ahsan, M. J. (2021). Machine Learning in Drug Discovery: A Review. *Artificial Intelligence Review*, 55(3), 1947–1999. <https://doi.org/10.1007/s10462-021-10058-4>.

14. Xue L. C., Dobbs, D., Bonvin, A. M., & Honavar, V. (2015). Computational prediction of protein interfaces: A review of data driven methods. *FEBS Letters*, 589(23), 3516–3526. <https://doi.org/10.1016/j.febslet.2015.10.003>.
15. Lim, H., Cankara, F., Tsai, C., Keskin, O., Nussinov, R., & Gursoy, A. (2022). Artificial intelligence approaches to human-microbiome protein–protein interactions. *Current Opinion in Structural Biology*, 73, 102328. <https://doi.org/10.1016/j.sbi.2022.102328>.
16. Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., Tunyasuvunakool, K., Bates, R., Židek, A., Potapenko, A., Bridgland, A., Meyer, C., Kohl, S. a. A., Ballard, A. J., Cowie, A., Romera-Paredes, B., Nikolov, S., Jain, R., Adler, J., . . . Hassabis, D. (2021). Highly accurate protein structure prediction with AlphaFold. *Nature*, 596(7873), 583–589. <https://doi.org/10.1038/s41586-021-03819-2>.
17. Powles, J., & Hodson, H. (2017). Google DeepMind and healthcare in an age of algorithms. *Health and Technology*, 7(4), 351–367. <https://doi.org/10.1007/s12553-017-0179-1>.
18. Wang, P., Zheng, S., Jiang, Y., Li, C., Liu, J., Wen, C., Patronov, A., Qian, D., Chen, H., & Yang, Y. (2021). X-DPI: A structure-aware multi-modal deep learning model for drug-protein interactions prediction. *bioRxiv (Cold Spring Harbor Laboratory)*. <https://doi.org/10.1101/2021.06.17.448780>.
19. Jimenes-Vargas, K., Pazos, A., Munteanu, C. R., Perez-Castillo, Y., & Tejera, E. (2024). Prediction of compound-target interaction using several artificial intelligence algorithms and comparison with a consensus-based strategy. *Journal of Cheminformatics*, 16(1). <https://doi.org/10.1186/s13321-024-00816-1>.
20. Cichońska, A., Ravikumar, B., & Rahman, R. (2024). AI for targeted polypharmacology: The next frontier in drug discovery. *Current Opinion in Structural Biology*, 84, 102771. <https://doi.org/10.1016/j.sbi.2023.102771>.

21. Koh, D., Papanikolaou, N., Bick, U., Illing, R., Kahn, C. E., Kalpathi-Cramer, J., Matos, C., Martí-Bonmatí, L., Miles, A., Mun, S. K., Napel, S., Rockall, A., Sala, E., Strickland, N., & Prior, F. (2022). Artificial intelligence and machine learning in cancer imaging. *Communications Medicine*, 2(1). <https://doi.org/10.1038/s43856-022-00199-0>.
22. Magill, E., Demartis, S., Gavini, E., Permana, A. D., Thakur, R. R. S., Adrianto, M. F., Waite, D., Glover, K., Picco, C. J., Korelidou, A., Detamornrat, U., Vora, L. K., Li, L., Anjani, Q. K., Donnelly, R. F., Domínguez-Robles, J., & Larrañeta, E. (2023). Solid implantable devices for sustained drug delivery. *Advanced Drug Delivery Reviews*, 199, 114950. <https://doi.org/10.1016/j.addr.2023.114950>.
23. Akbar, Wen M, Zhang Z, Niu S, Sha H, Yang R, Yun Y, Lu H. Deep-learning-based drug–target interaction prediction. *Journal of proteome research*. 2017 Apr 7;16(4):1401-9. R., Bashour, H., Rawat, P., Robert, P. A., Smorodina, E., Cotet, T., Flem-Karlsen, K., Frank, R., Mehta, B. B., Vu, M. H., Zengin, T., Gutierrez-Marcos, J., Lund-Johansen, F., Andersen, J. T., & Greiff, V. (2022). Progress and challenges for the machine learning-based design of fit-for-purpose monoclonal antibodies. *mAbs*, 14(1). <https://doi.org/10.1080/19420862.2021.2008790>.
24. Vora, L. K., Gholap, A. D., Jetha, K., Thakur, R. R. S., Solanki, H. K., & Chavda, V. P. (2023). Artificial Intelligence in Pharmaceutical Technology and Drug Delivery Design. *Pharmaceutics*, 15(7), 1916. <https://doi.org/10.3390/pharmaceutics15071916>.
25. Vora, L. K., Gholap, A. D., Jetha, K., Thakur, R. R. S., Solanki, H. K., & Chavda, V. P. (2023). Artificial Intelligence in Pharmaceutical Technology and Drug Delivery Design. *Pharmaceutics*, 15(7), 1916. <https://doi.org/10.3390/pharmaceutics15071916>.